Skip to main content

The art of forgetting

Forget AUPH. 


Really.  Just forget it.  Get busy with pottery, or gardening, or take a bike ride. But forget you own this stock, because if you don't you might start trying to trade the waves, or maybe sell and buy something shiny. And you'd regret that, when the rest of us are overjoyed when we wakeup one fine morning when the company has been sold at $40 per share.

So just forget about it.

TC


Comments

  1. vidpok45August 24, 2017 at 7:54 PM

    This year is flying by, two thirds over. Then 2 fast years go by and the drug should get approval. Buyout for 37 -60 by then.

    ReplyDelete
    Replies
    1. Trading CyclistAugust 24, 2017 at 8:24 PM

      I am happy to wait, and feel helthier now that I no longer frequent LieHub. What a horrid way to waste time.

      Delete
  2. vidpok45August 25, 2017 at 8:24 AM

    At least we can wait in style with the Ariad winnings

    ReplyDelete
  3. vidpok45August 26, 2017 at 12:51 PM

    Nice reply to BR's latest stupid post tonight by zzaatt. If AUPH goes to 4 which could happen if the market crashes, I am sure many of us have funds in reserve to buy the hell out of it. Not that I am hoping that will happen, I have enough shares already. Actually with the incipient news about the second indication, if the market crashes a lot of scared money may be headed in AUPH's direction as I think AUPH may be considered a somewhat safe harbor as it years away from having an approved product. No matter what occurs this Fall, there is absolutely no good reason to sell that anyone has found. Only ridiculous statements like the sp HAS to stay above a certain number without any reason as to why. Assholes like BR like to get weak retailers to doubt this investment. All that does is move the weak shares into stronger hands, ultimately helping the rest of us. So good luck with that.

    ReplyDelete

Post a Comment

Popular posts from this blog

June 6, 2017. Buy Out at 63?

Take a spin on our BO pricing model! The Trading Cyclist Our model is generating a range of $35-63 BO PPS , per the low/high case scenarios below - where only the Voc  price  is different (25 k vs 50k). My hunch is that this is both conservative and in the ballpark.  It's conservative b/c: 1) patient population is consistent with Aurinia's projection; 2) assumes only 35% of population on treatment; 3) assumes 75% discount for European market; 4) pricing is at 50% of range projected by Aurinia; 5) uses target P/S ratio of 3, which is below Biotech industry average of 5.0.  Outcome   Patient Pool  (Same for both Scenarios)  Pricing :  Price/Sales ratio   Here's the  Link to the model Low end BO PPS w/30% discount:  $35  ($50 no discount)  High End BO PPS w/30% discount  $63  ($90 no discount)  Prev: 26.5 per 100,000 (Based on epidemiological study)  Total Patient po...
25 comments
Read more

June 8, 2017: The case for early approval of Voclosporin

Voclosporin will likely be approved well before the P3 trial runs it course. Here's how it's going to work.  First, there's a legal and regulatory path for this approval .  While I quote the relevant passage below, here's the link to the  FDA Regulations , as well as  a   list of drugs   t hat received accelerated approval.  Sec. 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoin t that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. Approval under this section will be subject to the requirement that ...
16 comments
Read more

iHub has been hijacked by trolls

Yup. iHub can't get rid of "Biotech Researcher," aka BR.  It's both a win for BR (the troll), and a huge loss for iHub. Their platform loses value and credibility when they refuse to take action on perma-trolls that derail the discussion and distract investors from their efforts to just honestly share information and opinions on the equities they own. So shame on iHub for not taking action to resolve this. I'm going to cease and desist on posting there until the troll (BR) problem has been resolved, and credible, valuable posters have been reinstated. I've already cancelled my premium membership some time ago. I suggest you do the same. With kind regards to all Trading Cyclist (aka TC)
53 comments
Read more